Generated by AI
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates for hard-to-treat cancers and viral diseases. Its leading program is Annamycin, also known as naxtarubicin, a next-generation anthracycline being evaluated in combination with cytarabine for adults with relapsed or refractory acute myeloid leukemia. The company’s research focuses on medicines designed to address treatment resistance and improve the delivery and tolerability of established anticancer approaches. Its oncology pipeline targets serious malignancies, while its broader development activities include antiviral applications and other disease areas where existing therapies remain limited. Moleculin Biotech, Inc. operates within the biotechnology and pharmaceutical market, collaborating across drug discovery, preclinical research, clinical development, regulatory activities, and potential commercialization. As a clinical-stage developer, its role is centered on advancing proprietary drug candidates through clinical testing rather than supplying marketed medicines across a broad commercial portfolio. The company is headquartered in Houston, Texas, and serves the specialized global market for innovative therapies addressing significant unmet medical needs.
Website5300 Memorial Drive
Houston, TX, 77007
United States
The latest articles about MBRX.
Summary of Oct 27's posts. Generated by AI.
Summary of Nov 3's posts. Generated by AI.
Summary of Apr 23's posts. Generated by AI.
Summary of Oct 20's posts. Generated by AI.
Investors talking about MBRX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.